Rituxan (rituximab) [product monograph]. HC.

Regulatory approval published by the Health Canada.

Citation

Hoffmann-La Roche Limited. Rituxan (rituximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071131.PDF. Revised June 2023. Accessed June 2025.

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
RITUXAN (rituximab for injection) is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin’s lymphoma. 2
RITUXAN (rituximab for injection) is indicated for the treatment of patients with CD20 positive, diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. 2
RITUXAN (rituximab for injection) is indicated for the treatment of patients with previously untreated Stage III/IV follicular, CD20 positive, B-cell non-Hodgkin's lymphoma in combination with CVP (cyclophosphamide, vincristine and prednisolone) chemotherapy. 1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) CD20 + Non-Hodgkin Lymphoma Rituximab
Sensitivity (+) CD20 + Follicular Lymphoma Rituximab
Sensitivity (+) CD20 + Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
Sensitivity (+) CD20 + Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine
Sensitivity (+) CD20 + Follicular Lymphoma Cyclophosphamide, Prednisolone, Rituximab, Vincristine